Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use.
Johnny L Matson, Jill C Fodstad, Daniene Neal...
https://pubmed.ncbi.nlm.nih.gov/19720497/Actively Recruiting
Led by University Hospitals Cleveland Medical Center · Updated on 2026-07-06
25
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of deutetrabenazine on tardive dyskinesia TD in adults with intellectual and developmental disabilities IDD who have not been previously treated for TD. This open-label Phase 4 study aims to compare treatment responses in this group to published results from patients without IDD. The study will also assess safety, changes in daily living activities, quality of life, and caregiver burden using validated measurement tools. Participants will receive deutetrabenazine oral capsules with doses titrated from 12 mg to 24 mg per day over 24 weeks. Those taking strong CYP2D6 inhibitors will maintain the 24 mg dose throughout. The study involves five visits baseline, 3 weeks, 6 weeks, 12 weeks, and 24 weeks. There is no comparison group instead, responses will be compared to previous research that led to FDA approval. During the study, participants will undergo assessments including the Abnormal Involuntary Movement Scale AIMS, caregiver and clinician global impression scales, and questionnaires measuring activities of daily living, quality of life, caregiver burden, and impact of TD. Researchers will monitor safety, adherence, and treatment effects over the 24-week period. The total involvement includes scheduled visits and evaluations to track changes from baseline through the treatment duration.
CONDITIONS
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
M
Melissa Stasko, JD, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospitals Cleveland Medical Center
Lead Sponsor
Teva Pharmaceuticals USA
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Deutetrabenazine Oral Capsule (up to 24 mg/day) | Antipsychotic medication adjustment, dose reduction, or switch with monitoring for TD |
|---|---|---|
| What it is | Open-label oral treatment with deutetrabenazine for 24 weeks, aiming to reduce tardive dyskinesia symptoms in adults with intellectual or developmental disabilities. | The principal current-care approach consists of review, dose adjustment, or switch of antipsychotic medications, plus observation and monitoring for TD symptoms. |
| Primary use | Studied as a means to reduce involuntary movement symptoms of tardive dyskinesia in adults with intellectual/developmental disabilities. | Used to manage tardive dyskinesia by reducing antipsychotic exposure and monitoring for improvement or progression. |
| How it is given/performed | Participants take deutetrabenazine oral capsules daily, with doses titrated up to 24 mg/day, for 24 weeks under supervision. | Antipsychotic doses are reviewed and reduced as tolerated, or switched to alternative agents; patients are monitored at regular intervals for changes in TD symptoms. |
| Evidence status | Efficacy and safety are under investigation in this open-label trial. Prior randomized studies of deutetrabenazine show benefit in TD, but evidence is limited for the intellectual/developmental disability population. | Dose adjustment or switch of antipsychotic medication can help reduce TD risk and manage symptoms, but effectiveness in reversing established TD is often limited, especially for patients with long-term antipsychotic use. |
| Important limitations | Trial is open-label and single-group, so results may be subject to placebo effect and lack of randomized control. Evidence about deutetrabenazine's use in intellectual/developmental disability is still emerging. | Adjustment or switching of antipsychotic medications may not resolve established TD, and symptom improvement is often modest. Monitoring and management can be complicated for patients with intellectual disabilities due to communication and behavioral challenges. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive deutetrabenazine oral capsules with doses adjusted from 12 mg to 24 mg per day over 24 weeks.
5 visits: baseline, 3, 6, 12, and 24 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Johnny L Matson, Jill C Fodstad, Daniene Neal...
https://pubmed.ncbi.nlm.nih.gov/19720497/Gerda M de Kuijper, Pieter J Hoekstra
https://pubmed.ncbi.nlm.nih.gov/27529770/John M Kane, Christoph U Correll, Andrew A Nierenberg...
https://pubmed.ncbi.nlm.nih.gov/29742330/Thomas R E Barnes
https://pubmed.ncbi.nlm.nih.gov/14870947/Scott W Woods, Hal Morgenstern, John R Saksa...
https://pubmed.ncbi.nlm.nih.gov/20156410/Mark Stacy, Martha Sajatovic, John M Kane...
https://pubmed.ncbi.nlm.nih.gov/31234240/Rakesh Jain, Rajeev Ayyagari, Debbie Goldschmidt...
https://pubmed.ncbi.nlm.nih.gov/38015301/Silke Schmidt, Mick Power, Ann Green...
https://pubmed.ncbi.nlm.nih.gov/20478692/Christoph U Correll, John M Kane, Leslie L Citrome
https://pubmed.ncbi.nlm.nih.gov/29022654/J A Tsiouris
https://pubmed.ncbi.nlm.nih.gov/20122096/University Hospitals Cleveland Medical Center
Lead Sponsor
Teva Pharmaceuticals USA
Collaborating Sponsor